TABLE 2.
Tumor characteristics and pathologic outcomes of prostate cancer patients with biopsy Gleason ≤6 disease following radical prostatectomy at University of Pennsylvania, 1990–2012.
| Caucasian Cohort n=760 |
% | African-American Cohort n=176 |
% | p- Value | |
|---|---|---|---|---|---|
| Age, Y | 0.04 | ||||
| Median | 59 | 58 | |||
| mean | 58.9 | 57.8 | |||
| IQR | 54–64 | 52–62 | |||
|
| |||||
| iPSA ng/ml | 0.09 | ||||
| 0–4.0 | 215 | 29 | 48 | 28 | |
| 4.1–10 | 468 | 62 | 101 | 58 | |
| 10.1 – 20 | 62 | 8 | 18 | 10 | |
| > 20 | 8 | 1 | 6 | 4 | |
| median | 5 | 5.2 | |||
| mean | 5.7 | 6.67 | |||
| IQR | 4 – 6.4 | 4.1 – 8.1 | |||
|
| |||||
| Clinical Stage | 0.2 | ||||
| T1A-C | 594 | 82 | 145 | 83 | |
| T2A | 112 | 15 | 23 | 15 | |
| T2B | 8 | 1 | 5 | 1 | |
| T2C | 12 | 2 | 1 | 1 | |
|
| |||||
| Adverse pathologic features‡ | 0.2 | ||||
| 0 | 575 | 76 | 122 | 69 | |
| 1 | 92 | 12 | 25 | 14 | |
| >2 | 93 | 12 | 29 | 17 | |
|
| |||||
| Seminal Vesicle invasion | 17 | 2 | 14 | 8 | <0.001 |
|
| |||||
| Extraprostatic spread | 150 | 20 | 44 | 25 | 0.12 |
|
| |||||
| Lymph Node Involvement | 2 | 0.3 | 0 | 0 | 0.5 |
|
| |||||
| Positive surgical margin | 119 | 16 | 29 | 17 | 0.76 |
NOTE. Boldfaced values represent statistically significant differences between groups.
Abbreviations: iPSA- initial Prostate-specific antigen, IQR- interquartile range;
‡
Adverse pathologic features: extraprostatic extension, seminal vesicle invasion, positive surgical margin and/or lymph node involvement.